Fineline Cube

Follow:
14682 Articles
Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma
CompanyDrug

Chipscreen Biosciences Secures NMPA IND Acceptance for CS23546 – Oral Small‑Molecule PD‑L1 Inhibitor Advancing in Relapsed or Refractory Lymphoma

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs

Takeda Launches Oveporexton in Japan and China – Novel Oral OX2R Agonist for Narcolepsy Type 1 Now Commercially Available
CompanyDrug

Takeda Launches Oveporexton in Japan and China – Novel Oral OX2R Agonist for Narcolepsy Type 1 Now Commercially Available

Northland Biotech's Sedominji Completes First National Shipment – World's First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces
CompanyDrug

Northland Biotech’s Sedominji Completes First National Shipment – World’s First Approved HGF Naked Plasmid Gene Therapy Reaches CLI Patients in Nine Provinces

GeneScience's GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody
CompanyDrug

GeneScience’s GenSci161 Wins NMPA Acceptance for Recurrent Pericarditis Clinical Trial – Novel Fully Human IL‑1α/IL‑1β Bispecific Antibody

Youcare Pharmaceutical's YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program
CompanyDrug

Youcare Pharmaceutical’s YKYY036 Wins Dual Clinical Clearances from NMPA and FDA – GalNAc‑Conjugated siRNA Targeting INHBE Advances Global Obesity Program

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties
CompanyDeals

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo
CompanyDrug

Regeneron Reports Positive 84‑Week Phase 3 OPTIMA Results for Pasatru in FOP – No New Heterotopic Ossification Lesions After Week 56 vs Nine for Placebo

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn's Disease – 35.8% Achieved Endoscopic Remission
CompanyDrug

AbbVie Announces Phase 3 AFFIRM Data for SKYRIZI Subcutaneous Induction in Crohn’s Disease – 35.8% Achieved Endoscopic Remission

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children
CompanyDrug

Shenzhen Kangtai Initiates Phase I Trial of Self‑Developed DTaP Combination Vaccine – First‑in‑China Candidate for Adults, Adolescents and Children

J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn's Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success
CompanyDrug

J&J Announces Phase 3 Data Showing TREMFYA Delivers Combined Fistula Remission in Crohn’s Disease with Perianal Fistula – Only IL‑23 Inhibitor with Dedicated Trial Success

NHC and NDRC Launch Expansion and Quality Enhancement Plan for Rehabilitation and Nursing Care – 0.48 Beds per 1,000 Population Targeted by 2030
Policy / Regulatory

NHC and NDRC Launch Expansion and Quality Enhancement Plan for Rehabilitation and Nursing Care – 0.48 Beds per 1,000 Population Targeted by 2030